Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (7)

Search Parameters:
Authors = Monika Baumann

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 765 KiB  
Article
Glycemic Control Assessed by Intermittently Scanned Glucose Monitoring in Type 1 Diabetes during the COVID-19 Pandemic in Austria
by Katharina Secco, Petra Martina Baumann, Tina Pöttler, Felix Aberer, Monika Cigler, Hesham Elsayed, Clemens Martin Harer, Raimund Weitgasser, Ingrid Schütz-Fuhrmann and Julia Katharina Mader
Sensors 2024, 24(14), 4514; https://doi.org/10.3390/s24144514 - 12 Jul 2024
Cited by 1 | Viewed by 1329
Abstract
Objective: The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic. Methods: Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were [...] Read more.
Objective: The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic. Methods: Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were investigated retrospectively. The baseline characteristics were collected from electronic medical records. The data were examined over three periods of three months each: from 16th of March 2019 until 16th of June 2019 (pre-pandemic), from 1st of December 2019 until 29th of February 2020 (pre-lockdown) and from 16th of March 2020 until 16th of June 2020 (lockdown 2020), representing the very beginning of the COVID-19 pandemic and the first Austrian-wide lockdown. Results: For the main analysis, 64 individuals with T1D (22 female, 42 male), who had a mean glycated hemoglobin (HbA1c) of 58.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration 13.5 years (5.5 to 22.0 years) were included in the analysis. The time in range (TIR[70–180mg/dL]) was the highest percentage of measures within all three studied phases, but the lockdown 2020 phase delivered the best data in all these cases. Concerning the time below range (TBR[<70mg/dL]) and the time above range (TAR[>180mg/dL]), the lockdown 2020 phase also had the best values. Regarding the sensitivity analysis, 80 individuals with T1D (26 female, 54 male), who had a mean HbA1c of 57.5 mmol/mol (51.0 to 69.3 mmol/mol) and a mean diabetes duration of 12.5 years (5.5 to 20.7 years), were included. The TIR[70–180mg/dL] was also the highest percentage of measures within all three studied phases, with the lockdown 2020 phase also delivering the best data in all these cases. The TBR[<70mg/dL] and the TAR[>180mg/dL] underscored the data in the main analysis. Conclusion: Superior glycemic control, based on all parameters analyzed, was achieved during the first Austrian-wide lockdown compared to prior periods, which might be a result of reduced daily exertion or more time spent focusing on glycemic management. Full article
(This article belongs to the Section Biosensors)
Show Figures

Figure 1

17 pages, 2309 KiB  
Article
Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany—Results from the SeBluCo Study 2020–2022
by Ruth Offergeld, Karina Preußel, Thomas Zeiler, Konstanze Aurich, Barbara I. Baumann-Baretti, Sandra Ciesek, Victor M. Corman, Viktoria Dienst, Christian Drosten, Siegfried Görg, Andreas Greinacher, Marica Grossegesse, Sebastian Haller, Hans-Gert Heuft, Natalie Hofmann, Peter A. Horn, Claudia Houareau, Ilay Gülec, Carlos Luis Jiménez Klingberg, David Juhl, Monika Lindemann, Silke Martin, Hannelore K. Neuhauser, Andreas Nitsche, Julia Ohme, Sven Peine, Ulrich J. Sachs, Lars Schaade, Richard Schäfer, Heinrich Scheiblauer, Martin Schlaud, Michael Schmidt, Markus Umhau, Tanja Vollmer, Franz F. Wagner, Lothar H. Wieler, Hendrik Wilking, Malte Ziemann, Marlow Zimmermann and Matthias an der Heidenadd Show full author list remove Hide full author list
Pathogens 2023, 12(4), 551; https://doi.org/10.3390/pathogens12040551 - 2 Apr 2023
Cited by 7 | Viewed by 8675
Abstract
SARS-CoV-2 serosurveillance is important to adapt infection control measures and estimate the degree of underreporting. Blood donor samples can be used as a proxy for the healthy adult population. In a repeated cross-sectional study from April 2020 to April 2021, September 2021, and [...] Read more.
SARS-CoV-2 serosurveillance is important to adapt infection control measures and estimate the degree of underreporting. Blood donor samples can be used as a proxy for the healthy adult population. In a repeated cross-sectional study from April 2020 to April 2021, September 2021, and April/May 2022, 13 blood establishments collected 134,510 anonymised specimens from blood donors in 28 study regions across Germany. These were tested for antibodies against the SARS-CoV-2 spike protein and nucleocapsid, including neutralising capacity. Seroprevalence was adjusted for test performance and sampling and weighted for demographic differences between the sample and the general population. Seroprevalence estimates were compared to notified COVID-19 cases. The overall adjusted SARS-CoV-2 seroprevalence remained below 2% until December 2020 and increased to 18.1% in April 2021, 89.4% in September 2021, and to 100% in April/May 2022. Neutralising capacity was found in 74% of all positive specimens until April 2021 and in 98% in April/May 2022. Our serosurveillance allowed for repeated estimations of underreporting from the early stage of the pandemic onwards. Underreporting ranged between factors 5.1 and 1.1 in the first two waves of the pandemic and remained well below 2 afterwards, indicating an adequate test strategy and notification system in Germany. Full article
(This article belongs to the Special Issue Transfusion-Transmissible Infections and Epidemiological Surveillance)
Show Figures

Figure 1

10 pages, 1842 KiB  
Brief Report
Towards Auditory Profile-Based Hearing-Aid Fittings: BEAR Rationale and Clinical Implementation
by Raul Sanchez-Lopez, Mengfan Wu, Michal Fereczkowski, Sébastien Santurette, Monika Baumann, Borys Kowalewski, Tobias Piechowiak, Nikolai Bisgaard, Gert Ravn, Sreeram Kaithali Narayanan, Torsten Dau and Tobias Neher
Audiol. Res. 2022, 12(5), 564-573; https://doi.org/10.3390/audiolres12050055 - 9 Oct 2022
Cited by 2 | Viewed by 3242
Abstract
(1) Background: To improve hearing-aid rehabilitation, the Danish ‘Better hEAring Rehabilitation’ (BEAR) project recently developed methods for individual hearing loss characterization and hearing-aid fitting. Four auditory profiles differing in terms of audiometric hearing loss and supra-threshold hearing abilities were identified. To enable auditory [...] Read more.
(1) Background: To improve hearing-aid rehabilitation, the Danish ‘Better hEAring Rehabilitation’ (BEAR) project recently developed methods for individual hearing loss characterization and hearing-aid fitting. Four auditory profiles differing in terms of audiometric hearing loss and supra-threshold hearing abilities were identified. To enable auditory profile-based hearing-aid treatment, a fitting rationale leveraging differences in gain prescription and signal-to-noise (SNR) improvement was developed. This report describes the translation of this rationale to clinical devices supplied by three industrial partners. (2) Methods: Regarding the SNR improvement, advanced feature settings were proposed and verified based on free-field measurements made with an acoustic mannikin fitted with the different hearing aids. Regarding the gain prescription, a clinically feasible fitting tool and procedure based on real-ear gain adjustments were developed. (3) Results: Analyses of the collected real-ear gain and SNR improvement data confirmed the feasibility of the clinical implementation. Differences between the auditory profile-based fitting strategy and a current ‘best practice’ procedure based on the NAL-NL2 fitting rule were verified and are discussed in terms of limitations and future perspectives. (4) Conclusion: Based on a joint effort from academic and industrial partners, the BEAR fitting rationale was transferred to commercially available hearing aids. Full article
(This article belongs to the Special Issue Translational Research in Audiology)
Show Figures

Figure 1

14 pages, 2155 KiB  
Article
Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
by Monika Lindemann, Charleen Baumann, Benjamin Wilde, Anja Gäckler, Lara Meller, Peter A. Horn, Adalbert Krawczyk and Oliver Witzke
Vaccines 2022, 10(6), 844; https://doi.org/10.3390/vaccines10060844 - 26 May 2022
Cited by 9 | Viewed by 3373
Abstract
Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve female [...] Read more.
Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve female and 17 male KTX recipients were vaccinated twice with the adjuvanted, recombinant zoster vaccine Shingrix™, which contains the VZV glycoprotein E (gE). Cellular immunity against various VZV antigens was analyzed with interferon-gamma ELISpot. We observed the strongest vaccination-induced changes after stimulation with a gE peptide pool. One month after the second vaccination, median responses were 8.0-fold higher than the responses prior to vaccination (p = 0.0006) and 4.8-fold higher than responses after the first vaccination (p = 0.0007). After the second vaccination, we observed an at least twofold increase in ELISpot responses towards gE peptides in 22 out of 29 patients (76%). Male sex, good kidney function, early time point after transplantation, and treatment with tacrolimus or mycophenolate were correlated significantly with higher VZV-specific cellular immunity, whereas diabetes mellitus was correlated with impaired responses. Thus, our data indicate that vaccination with Shingrix™ significantly augmented cellular, VZV gE-specific immunity in KTX recipients, which was dependent on several covariates. Full article
(This article belongs to the Special Issue Vaccine Immunology)
Show Figures

Figure 1

18 pages, 5405 KiB  
Article
Frequent Occurrence of Simultaneous Infection with Multiple Rotaviruses in Swiss Pigs
by Sibylle Baumann, Titus Sydler, Giuliana Rosato, Monika Hilbe, Dolf Kümmerlen, Xaver Sidler and Claudia Bachofen
Viruses 2022, 14(5), 1117; https://doi.org/10.3390/v14051117 - 23 May 2022
Cited by 7 | Viewed by 3360
Abstract
Rotavirus (RV) infections are the most important viral cause of diarrhea in piglets in Switzerland and are thought to cause substantial economic losses to the pig industry. However, no data are available on the occurrence and dynamics of the main porcine RV species, [...] Read more.
Rotavirus (RV) infections are the most important viral cause of diarrhea in piglets in Switzerland and are thought to cause substantial economic losses to the pig industry. However, no data are available on the occurrence and dynamics of the main porcine RV species, namely RVA, RVB, and RVC, and the diversity of the circulating strains. We therefore tested fecal samples from a cross-sectional (n = 95) and a longitudinal (n = 48) study for RVA, RVB, and RVC by real-time RT-PCR and compared the results of the cross-sectional study to postmortem findings. In addition, eight samples were fully genotyped by using next-generation sequencing. In the cross-sectional study, triple RV infections significantly correlated with diarrhea and wasting and were most frequent in the weaned age group. In the longitudinal study, the shedding of RV peaked one week after weaning and decreased thereafter. Here, mainly double infections were seen, and only a few animals showed diarrhea. The full-genome sequencing revealed a genotype pattern similar to other European countries and, importantly, co-infection by up to four RVA strains. Our results imply that the weaning of piglets may trigger not only RV shedding but facilitate co-infection of multiple RV species and strains in the same host. Full article
(This article belongs to the Special Issue Enteric and Respiratory Viruses in Animals 3.0)
Show Figures

Figure 1

14 pages, 1777 KiB  
Article
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
by Linn Woelber, Monika Hampl, Christine zu Eulenburg, Katharina Prieske, Johanna Hambrecht, Sophie Fuerst, Ruediger Klapdor, Sabine Heublein, Paul Gass, Annika Rohner, Ulrich Canzler, Sven Becker, Mareike Bommert, Dirk Bauerschlag, Agnieszka Denecke, Lars Hanker, Ingo Runnebaumn, Dirk M. Forner, Fabienne Schochter, Maximilian Klar, Roxana Schwab, Melitta Koepke, Matthias Kalder, Peer Hantschmann, Dominik Ratiu, Dominik Denschlag, Willibald Schroeder, Benjamin Tuschy, Klaus Baumann, Alexander Mustea, Philipp Soergel, Holger Bronger, Gerd Bauerschmitz, Jens Kosse, Martin C. Koch, Atanas Ignatov, Jalid Sehouli, Christian Dannecker, Sven Mahner and Anna Jaegeradd Show full author list remove Hide full author list
Cancers 2022, 14(2), 418; https://doi.org/10.3390/cancers14020418 - 14 Jan 2022
Cited by 5 | Viewed by 2909
Abstract
The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at [...] Read more.
The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b. Full article
(This article belongs to the Special Issue Recent Advances in Vulvar Cancer)
Show Figures

Figure 1

18 pages, 3522 KiB  
Article
Formulation of Cannabidiol in Colloidal Lipid Carriers
by Nadine Monika Francke, Frederic Schneider, Knut Baumann and Heike Bunjes
Molecules 2021, 26(5), 1469; https://doi.org/10.3390/molecules26051469 - 8 Mar 2021
Cited by 27 | Viewed by 5946
Abstract
In this study, the general processability of cannabidiol (CBD) in colloidal lipid carriers was investigated. Due to its many pharmacological effects, the pharmaceutical use of this poorly water-soluble drug is currently under intensive research and colloidal lipid emulsions are a well-established formulation option [...] Read more.
In this study, the general processability of cannabidiol (CBD) in colloidal lipid carriers was investigated. Due to its many pharmacological effects, the pharmaceutical use of this poorly water-soluble drug is currently under intensive research and colloidal lipid emulsions are a well-established formulation option for such lipophilic substances. To obtain a better understanding of the formulability of CBD in lipid emulsions, different aspects of CBD loading and its interaction with the emulsion droplets were investigated. Very high drug loads (>40% related to lipid content) could be achieved in emulsions of medium chain triglycerides, rapeseed oil, soybean oil and trimyristin. The maximum CBD load depended on the type of lipid matrix. CBD loading increased the particle size and the density of the lipid matrix. The loading capacity of a trimyristin emulsion for CBD was superior to that of a suspension of solid lipid nanoparticles based on trimyristin (69% vs. 30% related to the lipid matrix). In addition to its localization within the lipid core of the emulsion droplets, cannabidiol was associated with the droplet interface to a remarkable extent. According to a stress test, CBD destabilized the emulsions, with phospholipid-stabilized emulsions being more stable than poloxamer-stabilized ones. Furthermore, it was possible to produce emulsions with pure CBD as the dispersed phase, since CBD demonstrated such a pronounced supercooling tendency that it did not recrystallize, even if cooled to −60 °C. Full article
(This article belongs to the Special Issue Nanosystems in Pharmaceutical Technology)
Show Figures

Figure 1

Back to TopTop